These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17116438)

  • 1. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited.
    Cunha BA
    Med Clin North Am; 2006 Nov; 90(6):1089-107. PubMed ID: 17116438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
    Bishburg E; Bishburg K
    Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.
    Paterson DL
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S14-20. PubMed ID: 18713045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
    Li J; Nation RL; Turnidge JD; Milne RW; Coulthard K; Rayner CR; Paterson DL
    Lancet Infect Dis; 2006 Sep; 6(9):589-601. PubMed ID: 16931410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term observations on the etiology and antibiotic resistance in urinary infections (1971-1987)].
    Lach S; Crevatin E; Modonutti GB; Daris F; Nedoclan G
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):449-54. PubMed ID: 2152305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The search for new antimicrobials: why we need new options.
    Zinner SH
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):907-13. PubMed ID: 16307503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Bassetti M; Righi E; Dimopoulos G
    Future Microbiol; 2014; 9(9):1053-69. PubMed ID: 25340835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.
    Entenza JM; Moreillon P
    Int J Antimicrob Agents; 2009 Jul; 34(1):8.e1-9. PubMed ID: 19162449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxins: a word of caution for prudent use of valuable "old antibiotics".
    Falagas ME; Kasiakou SK; Michalopoulos A
    Infect Control Hosp Epidemiol; 2006 Sep; 27(9):995. PubMed ID: 16941333
    [No Abstract]   [Full Text] [Related]  

  • 17. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenario.
    Shakti L; Veeraraghavan B
    Indian J Med Microbiol; 2015; 33(4):477-81. PubMed ID: 26470951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing use of colistin and polymyxin B in the critically ill.
    Nation RL; Li J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.